Nutriband CEO Publishes Letter to Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2025
0mins
Should l Buy NTRB?
Source: Newsfilter
Company Achievements and Future Goals: Nutriband Inc. has made significant progress in developing its AVERSA technology, which aims to create abuse-deterrent transdermal patches for medications like fentanyl and buprenorphine, with plans for clinical trials and NDA filing in 2025.
Financial Outlook and Partnerships: The company reported strong revenue from its subsidiary Pocono Pharma and has secured an exclusive partnership with Kindeva Drug Delivery to advance the commercialization of its products while expanding its intellectual property portfolio globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRB
Wall Street analysts forecast NTRB stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.460
Low
15.00
Averages
15.00
High
15.00
Current: 3.460
Low
15.00
Averages
15.00
High
15.00
No data
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NUTRIBAND INC - NAME CHOSEN FOR REGISTRATION WITH US PATENT AND TRADEMARK OFFICE
- Patent and Trademark Office Submission: A list of selected names has been submitted to the U.S. Patent and Trademark Office for registration.
- Nutriband Inc.: The submission is related to the company Nutriband Inc., indicating potential new branding or product developments.
See More
NUTRIBAND INC CHOOSES BRAND NAME FOR ABUSE-RESISTANT FENTANYL PATCH; PLANS FDA SUBMISSION
Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.
Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.
See More
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
See More
Nutriband Sells 90% of Subsidiary for $5M, No Dilution for Shareholders
- Strategic Transaction: Nutriband has agreed to sell 90% of its Pocono subsidiary for $5 million, which will add $5 million to the company's bottom line while ensuring no dilution for shareholders, reflecting the company's commitment to shareholder value.
- Shareholder Returns: In July 2025, Nutriband issued a 25% preferred stock dividend to all existing shareholders, allowing shareholders of record on July 25 to receive one preferred share for every four common shares held, thereby enhancing shareholder returns.
- Enhanced Patent Protection: In June 2025, Nutriband received patent number 12,318,492 from the USPTO, further strengthening its intellectual property protection for the AVERSA™ technology, laying the groundwork for future commercialization.
- Market Expansion: Nutriband successfully joined four indexes in 2025, including the Russell Microcap and Russell 3000E, which boosts the company's market visibility and investment appeal, indicating enhanced growth potential ahead.
See More
NUTRIBAND INC - NAME CHOSEN FOR REGISTRATION WITH US PATENT AND TRADEMARK OFFICE
- Patent and Trademark Office Submission: A list of selected names has been submitted to the U.S. Patent and Trademark Office for registration.
- Nutriband Inc.: The submission is related to the company Nutriband Inc., indicating potential new branding or product developments.
See More
NUTRIBAND INC CHOOSES BRAND NAME FOR ABUSE-RESISTANT FENTANYL PATCH; PLANS FDA SUBMISSION
Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.
Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.
See More
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
See More
Nutriband Sells 90% of Subsidiary for $5M, No Dilution for Shareholders
- Strategic Transaction: Nutriband has agreed to sell 90% of its Pocono subsidiary for $5 million, which will add $5 million to the company's bottom line while ensuring no dilution for shareholders, reflecting the company's commitment to shareholder value.
- Shareholder Returns: In July 2025, Nutriband issued a 25% preferred stock dividend to all existing shareholders, allowing shareholders of record on July 25 to receive one preferred share for every four common shares held, thereby enhancing shareholder returns.
- Enhanced Patent Protection: In June 2025, Nutriband received patent number 12,318,492 from the USPTO, further strengthening its intellectual property protection for the AVERSA™ technology, laying the groundwork for future commercialization.
- Market Expansion: Nutriband successfully joined four indexes in 2025, including the Russell Microcap and Russell 3000E, which boosts the company's market visibility and investment appeal, indicating enhanced growth potential ahead.
See More
